Magnetic Seed Localization

Magnetic Seed Localization (MSL) is a new technique to help Radiologists and Surgeons localize impalpable breast lesions.

Magseed® (the size of a grain of rice) is inserted into the lesion under image guidance, up to 30 days prior to surgery. This flexibility simplifies the scheduling of patients, and allows them to go straight to the OR on the day of surgery minimizing delays and enhancing the patient experience.

In the OR Magseed® is located using the Sentimag® probe and can be detected from any direction, regardless of seed orientation. The seed has no moving parts and can't be damaged when implanted. It is still detectable even if accidentally cut during dissection.

During surgery, through a combination of audio and visual feedback, the surgeon can use location of the seed to orientate the specimen and guide dissection.



Endomag:	1mm x 5mm
Delivery System:	18-gauge needle
Implantation:	Up to 30 days
Image Guidance:	Ultrasound of Mammography
Sensing Depth:	40mm - or greater with palpatation
Sensing Direction:	Detectable from any orientation
Sensing Accurary:	Pinpoint to withinn a few millimeters
Seed Signal:	No decay in signal over time No requirement for tissue contact Can't be damaged during placement Still detectable if accidentally cut
Feedback:	Real time audio and visual feedback
Bracketing:	Seeds 20mm apart or greater



Ultrasound visibility of Magseed®



X-Ray visibility of Magseed®

About Endomag

Endomag is dedicated to improving the global standard cancer care for everyone, everywhere, by developing a unique clinical platform that uses magnetic fields to power diagnostic and therapeutic devices. Endomag's first approved products form a minimally-invasive surgical guidance system to address unmet needs in work flow efficiency, availability and affordability for surgical oncology.

Sentimag® is the foundation of this system, and is the world's most sensitive handheld magnetic probe. Given its sensitivity, it can detect minute quantities of magnetic material in the body to guide surgeons in a lumpectomy using Magseed®, or to the lymph nodes first in line to drain from a tumor in a sentinel lymph node biopsy using Sienna+®.

Sentimag® launched in 2013 and, along with Sienna+®, has been used in over 12,000 sentinel lymph node biopsies in Europe and Australasia. In that time a number of multi-center clinical tria ls across Europe have completed. The most recent publication, a meta-analysis, concluded that Sienna+® is "non-inferior to the standard method [Tc99 + Blue Dye] for SLN detection in patients with clinically node-negative breast cancer"1.

Sentimag® and Magseed® have FDA 510(k) clearance and are available in the United States. Sienna+® is limited to investigational use only under an FDA-approved IDE.

Clinical references:

1. Teshome M, Wei C, Hunt KK, et al., Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. Ann Surg Oncol. 2016; 23(5): 1508-14.
2. Price eta (2018) Initial Clinical Experience with an inducible Magnetic Seed System for Preoperative Breast Lesion Localization. AJR AM J Roestgengol W1-W5. Arch Pathol Lab Med. 2017 Oct;141(10):1324-1329. doi: 10.5858/arpa.2017-0214-RA.Jeffries DO et al Localization for Breast Surgery The next Generation.
3. James R. Harvey1 ·et al (2018) Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study Breast Cancer Research and Treatment (2018) 169:531–536.

FOR MORE INFORMATION CONTACT YOUR PRODUCT SPECIALIST
Susan Ottley IN QUEENSLAND ON **00418 583 118** OR **sottley@ebosgroup.com.au**